argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia Gravis
September 15, 2023 01:00 ET
|
argenx SE
Positive opinion based on Phase 3 ADAPT-SC study demonstrating noninferior total IgG reduction at day 29 with subcutaneously (SC) administered efgartigimod, compared to intravenous (IV)...
argenx to Present at Upcoming Investor Conferences
August 30, 2023 01:00 ET
|
argenx SE
August 30, 2023Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,...
argenx Reports Half Year 2023 Financial Results and Provides Second Quarter Business Update
July 27, 2023 01:00 ET
|
argenx SE
$269 million in second quarter VYVGART® (efgartigimod alfa-fcab) global net product sales VYVGART® Hytrulo now available in the U.S. with first vials shipped in JulyGlobal VYVGART expansion...
argenx announces closing of global offering
July 24, 2023 16:30 ET
|
argenx SE
Regulated information – Inside information July 24, 2023, 4:30 PM ETJuly 24, 2023, 10:30 PM CET Amsterdam, the Netherlands — argenx SE (Euronext & Nasdaq: ARGX), a global immunology company...
argenx to Report Half Year 2023 Financial Results and Second Quarter Business Update on July 27, 2023
July 20, 2023 01:00 ET
|
argenx SE
July 20, 2023Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,...
argenx announces full exercise of underwriters’ option to purchase additional ADSs
July 19, 2023 17:58 ET
|
argenx SE
Regulated information — Inside information July 19, 2023, 11:58 PM CETJuly 19, 2023, 5:58 PM ET Amsterdam, the Netherlands — argenx SE (Euronext & Nasdaq: ARGX), a global immunology company...
argenx raises $1.1 billion in gross proceeds in a global offering
July 18, 2023 21:30 ET
|
argenx SE
Regulated information — Inside information July 18, 2023, 9:20 PM ET July 19, 2023, 3:20 AM CET Amsterdam, the Netherlands — argenx SE (Euronext & Nasdaq: ARGX), a global immunology...
argenx announces launch of proposed global offering
July 17, 2023 16:01 ET
|
argenx SE
Regulated information — Inside information argenx announces launch of proposed global offering July 17, 2023 Amsterdam, the Netherlands — argenx SE (Euronext & Nasdaq: ARGX), a global...
argenx Reports Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
July 17, 2023 01:00 ET
|
argenx SE
Study met primary endpoint (p=0.000039); VYVGART® Hytrulo demonstrated 61% reduction (HR: 0.39 95% CI: 0.25; 0.61) in risk of relapse versus placebo IgG autoantibodies shown to play significant role...
argenx and Zai Lab Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China
June 30, 2023 09:39 ET
|
argenx SE
First-and-only approved FcRn antagonist for gMG patients by NMPA68% of anti-AChR antibody positive gMG patients treated with VYVGART were responders (n=44/65) on the Myasthenia Gravis Activities of...